Welcome to our dedicated page for Surrozen news (Ticker: SRZN), a resource for investors and traders seeking the latest updates and insights on Surrozen stock.
Surrozen Inc (SRZN) is a clinical-stage biotechnology company pioneering regenerative therapies through targeted modulation of the Wnt signaling pathway. This page provides investors and researchers with timely updates on the company’s progress in developing treatments for severe liver diseases and retinal disorders.
Access official press releases, clinical trial announcements, and research milestones related to Surrozen’s proprietary platforms, including SWEETS and SWAP. Stay informed about regulatory developments, partnership agreements, and scientific breakthroughs in tissue-specific antibody therapies.
Our curated news collection serves as a neutral, comprehensive resource for tracking Surrozen’s advancements in early-phase trials and preclinical research. Bookmark this page for streamlined access to verified updates about the company’s innovative approach to activating the body’s natural repair mechanisms.
Surrozen (Nasdaq: SRZN), a biotechnology company focused on Wnt pathway therapeutics for severe eye diseases, has granted inducement stock options to four new non-executive employees. The grants, approved on September 2, 2025, cover 45,710 shares of common stock at an exercise price of $12.32 per share.
The stock options were awarded under Surrozen's 2025 Equity Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The options vest over four years, with 25% vesting after the first year and the remainder vesting monthly thereafter, subject to continued employment.
Surrozen (Nasdaq: SRZN), a biotechnology company focused on developing targeted therapeutics for severe eye diseases through Wnt pathway modulation, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
The presentation is scheduled for September 10, 2025, from 8:30 AM to 9:00 AM Pacific Time (11:30 AM to 12:00 PM Eastern Time). Investors can access the audio webcast through Surrozen's investor relations website, with a replay available afterward.
Surrozen (Nasdaq: SRZN), a biotechnology company focused on developing targeted therapeutics for the Wnt pathway with emphasis on severe eye diseases, has announced its participation in the Cantor Global Healthcare Conference 2025.
The company will participate in a fireside chat on September 4, 2025, from 8:00 - 8:30 AM Eastern Time. Investors can access the audio webcast through Surrozen's investor relations website, with a replay available afterward at www.surrozen.com.
Surrozen (NASDAQ:SRZN), a biotechnology company focused on Wnt pathway therapeutics for eye diseases, reported Q2 2025 financial results and significant organizational developments. The company ended Q2 with $90.4 million in cash, down from $101.6 million in Q1, and posted net income of $39.7 million ($2.55 per share).
Key developments include the appointment of Dr. Daniel Chao as VP of Clinical Development, formation of a Clinical Advisory Board with leading retinal specialists, and receipt of a U.S. patent for their SWAP™ technology. The company's lead candidates, SZN-8141 and SZN-8143, continue progressing, with an IND submission for SZN-8141 planned for 2026.
Research revenue was $1.0 million, while R&D expenses increased to $6.0 million from $5.3 million year-over-year. The significant net income was primarily driven by non-cash gains from changes in fair value of tranche liability and warrant liabilities.
Surrozen (Nasdaq: SRZN), a biotechnology company focused on developing targeted therapeutics that modulate the Wnt pathway for tissue repair and regeneration, particularly in severe eye diseases, has announced its participation in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference.
The presentation will be available starting at 7:00 AM Eastern Time on Wednesday, August 13, 2025. Investors can access the audio webcast through Surrozen's investor relations website, with a replay available afterward.
Surrozen (NASDAQ: SRZN) has been granted U.S. Patent No. 12,297,278 for its SWAP™ technology, expanding its intellectual property portfolio in Wnt pathway therapeutics. The patent covers tetravalent, multi-specific Wnt surrogates that utilize antibody-based molecules to target key receptors in the Wnt pathway.
The company's patent portfolio now includes 6 U.S. patents, 10 international patents, and multiple pending applications. The newly granted patent specifically covers technology involving two Frizzled (Fzd) binding regions and two LRP5/6 binding regions, connected via linker moieties. Surrozen has demonstrated that multivalent binding to Fzd and LRP is crucial for maximal signaling through selective surrogate Wnt molecules.
Surrozen (SRZN) reported its Q4 and full year 2024 financial results, highlighting a strategic focus on ophthalmology pipeline programs. The company secured a two-tranche financing of $175M in gross proceeds to fund multiple ophthalmology programs through Phase 1 studies.
Key financial metrics for 2024 include:
- Cash position of $34.6M as of December 31, 2024
- Additional gross proceeds of $76.4M from March 2025 financing
- Collaboration revenue of $10M from BI milestone
- Research and development expenses decreased to $21.1M from $27.2M in 2023
- Net loss increased to $63.6M compared to $43M in 2023
The company received confirmation that Boehringer will advance SZN-413 toward clinical testing and completed a research collaboration with TCGFB for antibody development targeting TGF-β.
Surrozen (NASDAQ: SRZN) announced a strategic shift to focus on ophthalmology programs, supported by an oversubscribed $175 million private placement. The funding will advance multiple eye disease treatments through Phase 1 studies.
The company's two lead candidates for retinopathies are SZN-8141 (Fzd4/VEGF) and SZN-8143 (Fzd4/VEGF/IL-6), targeting conditions like AMD, diabetic retinopathy, and other severe eye diseases. Both compounds have shown promise in preclinical models by stimulating Wnt signaling and promoting normal retinal vessel growth while inhibiting pathological vessel development.
Surrozen will discontinue the development of SZN-043 for severe alcohol-associated hepatitis, despite its safety profile, due to insufficient early clinical benefit signals. The private placement consists of two tranches: an initial $70 million closing around March 26, 2025, and a second $105 million tranche contingent on FDA clearance of the SZN-8141 IND, expected in 2026.
Surrozen (Nasdaq: SRZN), a biotech company focused on targeted therapeutics that activate the Wnt pathway for tissue repair, has announced its participation in two major healthcare investor conferences. CEO Craig Parker will present at the Guggenheim's Inaugural Healthcare Innovation Conference on November 13, 2024, with a fireside chat at 3:00 PM ET, and at the Stifel 2024 Healthcare Conference on November 19, 2024, presenting at 2:25 PM ET. Live audio webcasts will be available through Surrozen's investor website, with recordings archived for later access.
FAQ
What is the current stock price of Surrozen (SRZN)?
What is the market cap of Surrozen (SRZN)?
